Table 2.
Sociodemographic, laboratorial, and clinical information on mpox-related hospitalized participants according to HIV status (N = 43).
| HIV − (N = 19)a | HIV + (N = 24)a | Total (N = 43)a | P valueb | |
| Median age (IQR) | 30 (25–36) | 35 (30–42) | 31 (28–40) | 0.08 |
| Age range | 0.20 | |||
| 18–24 years | 3/19 (15.8%) | 1/24 (4.2%) | 4/43 (9.3%) | |
| 25–29 years | 6/19 (31.6%) | 3/24 (12.5%) | 9/43 (20.9%) | |
| 30–39 years | 7/19 (36.8%) | 12/24 (50%) | 19/43 (44.2%) | |
| ≥40 years | 3/19 (15.8%) | 8/24 (33.3%) | 11/43 (25.6%) | |
| Gender identity | 0.08 | |||
| Cisgender men | 16/19 (84.2%) | 24/24 (100%) | 40/43 (93%) | |
| Cisgender women | 3/19 (15.8%) | 0/24 | 3/43 (7%) | |
| Race | >0.99 | |||
| White | 7/18 (38.9%) | 9/21 (42.9%) | 16/39 (41.1%) | |
| Pardo or mixed | 5/18 (27.8%) | 5/21 (23.8%) | 10/39 (25.6%) | |
| Black | 6/18 (33.3%) | 7/21 (33.3%) | 13/39 (33.3%) | |
| Education | 0.13 | |||
| Primary | 13/19 (68.4%) | 10/24 (41.7%) | 23/43 (53.5%) | |
| Secondary | 1/19 (5.3%) | 1/24 (4.1%) | 2/43 (4.6%) | |
| Postsecondary | 5/19 (26.3%) | 13/24 (54.2%) | 18/43 (41.9%) | |
| Fever | 14/19 (73.7%) | 15/23 (65.2%) | 29/42 (69%) | 0.55 |
| Anogenital lesions | 9/19 (47.4%) | 20/24 (83.3%) | 29/43 (67.4%) | 0.01 |
| Time from symptoms onset to hospitalization (days, IQR) | 9 (8–11) | 8 (7–14) | 9 (7–12) | >0.99 |
| Length of hospitalization (days, IQR) | 7 (5–10) | 8 (4–14) | 7.5 (5–12) | 0.56 |
| Reason of hospitalization | ||||
| Pain control | 18/19 (94.7%) | 21/24 (87.5%) | 39/43 (90.7%) | 0.62 |
| Urological complication | 7/19 (36.8%) | 10/24 (41.7%) | 16/43 (37.21%) | 0.75 |
| Proctitis | 5/19 (26.3%) | 14/24 (58.3%) | 18/43 (41.9%) | 0.04 |
| Superbacterial infection | 11/19 (57.9%) | 13/24 (54.2%) | 24/43 (55.8%) | 0.81 |
| Ophthalmologic complications | 2/19 (10.5%) | 1/24 (4.2%) | 3/43 (7%) | 0.58 |
| Neuropsychiatric symptoms | 4/19 (21.1%) | 5/24 (20.8%) | 9/43 (20.9%) | >0.99 |
| Odynophagia | 6/19 (31.6%) | 5/24 (20.8%) | 11/43 (25.6%) | 0.49 |
| Need for invasive supportc | 0/19 | 8/23 (34.8%) | 8/42 (19.1%) | 0.01 |
| Urological or bowel obstruction | 1/19 (5.3%) | 3/23 (13%) | 4/42 (9.5%) | 0.61 |
| Use of opioids for pain control | 14/17 (82.4%) | 13/23 (56.5%) | 27/40 (67.5%) | 0.09 |
| Death | 0/19 | 2/24 (8.3%) | 2/43 (4.7%) | 0.50 |
IQR, interquartile range.
a
n (%); median (IQR).
b
Fisher's exact test; Wilcoxon rank sum test; Pearson's chi-squared test.
c
Invasive support included need for mechanical ventilation, vasoactive drugs, hemodialysis, venous or arterial lines and/or vesical catheterization.